27 results on '"McClintock, Shawn M."'
Search Results
2. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression
- Author
-
Zavaliangos-Petropulu, Artemis, McClintock, Shawn M., Khalil, Jacqueline, Joshi, Shantanu H., Taraku, Brandon, Al-Sharif, Noor B., Espinoza, Randall T., and Narr, Katherine L.
- Published
- 2023
- Full Text
- View/download PDF
3. Electroconvulsive therapy (ECT) for moderate-severity major depression among the elderly: Data from the pride study
- Author
-
Østergaard, Søren D., Speed, Maria S., Kellner, Charles H., Mueller, Martina, McClintock, Shawn M., Husain, Mustafa M., Petrides, Georgios, McCall, William V., and Lisanby, Sarah H.
- Published
- 2020
- Full Text
- View/download PDF
4. ElectroConvulsive therapy Cognitive Assessment (ECCA) tool: A new instrument to monitor cognitive function in patients undergoing ECT
- Author
-
Hermida, Adriana P., Goldstein, Felicia C., Loring, David W., McClintock, Shawn M., Weiner, Richard D., Reti, Irving M., Janjua, A. Umair, Ye, Zixun, Peng, Limin, Tang, Yi-lang, Galendez, Gail C., Husain, Mustafa M., Maixner, Daniel F., Riva-Posse, Patricio, and McDonald, William M.
- Published
- 2020
- Full Text
- View/download PDF
5. Effects of a right unilateral ultrabrief pulse electroconvulsive therapy course on health related quality of life in elderly depressed patients
- Author
-
McCall, W. Vaughn, Lisanby, Sarah H., Rosenquist, Peter B., Dooley, Mary, Husain, Mustafa M., Knapp, Rebecca G., Petrides, Georgios, Rudorfer, Matthew V., Young, Robert C., McClintock, Shawn M., Mueller, Martina, Prudic, Joan, Greenberg, Robert M., Weiner, Richard D., Bailine, Samuel H., Riley, Mary Anne, McCloud, Laryssa, and Kellner, Charles H.
- Published
- 2017
- Full Text
- View/download PDF
6. Cognitive effects of electroconvulsive therapy in depressed adolescents
- Author
-
Ghaziuddin, Neera, McClintock, Shawn M., Maixner, Daniel F., Miller, Leslie R., Husain, Mustafa, Wachtel, Lee E., Siddiqi, Shan H., Flood, Michael, Weinstein, Sally, Frye, Mark A., and Weiner, Richard D.
- Published
- 2024
- Full Text
- View/download PDF
7. Five-Year Longitudinal Evidence Supports the Safety and Efficacy of Electroconvulsive Therapy for Older Adults With Major Depressive Disorder.
- Author
-
McClintock, Shawn M. and Abbott, Christopher C.
- Abstract
The article presents an editorial paper entitled "Five-Year Longitudinal Evidence Supports the Safety and Efficacy of Electroconvulsive Therapy for Older Adults With Major Depressive Disorder," by Shawn M. McClintock, published in a previous issue.
- Published
- 2022
- Full Text
- View/download PDF
8. Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.
- Author
-
Lisanby, Sarah H., McClintock, Shawn M., McCall, William V., Knapp, Rebecca G., Cullum, C. Munro, Mueller, Martina, Deng, Zhi-De, Teklehaimanot, Abeba A., Rudorfer, Matthew V., Bernhardt, Elisabeth, Alexopoulos, George, Bailine, Samuel H., Briggs, Mimi C., Geduldig, Emma T., Greenberg, Robert M., Husain, Mustafa M., Kaliora, Styliani, Latoussakis, Vassilios, Liebman, Lauren S., and Petrides, Georgios
- Abstract
Objective: There is limited information regarding neurocognitive outcomes of right unilateral ultrabrief pulse width electroconvulsive therapy (RUL-UB ECT) combined with pharmacotherapy in older adults with major depressive disorder. We report longitudinal neurocognitive outcomes from Phase 2 of the Prolonging Remission in Depressed Elderly (PRIDE) study.Method: After achieving remission with RUL-UB ECT and venlafaxine, older adults (≥60 years old) were randomized to receive symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium) or pharmacotherapy-only. A comprehensive neuropsychological battery was administered at baseline and throughout the 6-month treatment period. Statistical significance was defined as a p-value of less than 0.05 (two-sided test).Results: With the exception of processing speed, there was statistically significant improvement across most neurocognitive measures from baseline to 6-month follow-up. There were no significant differences between the two treatment groups at 6 months on measures of psychomotor processing speed, autobiographical memory consistency, short-term and long-term verbal memory, phonemic fluency, inhibition, and complex visual scanning and cognitive flexibility.Conclusion: To our knowledge, this is the first report of neurocognitive outcomes over a 6-month period of an acute course of RUL-UB ECT followed by one of 2 strategies to prolong remission in older adults with major depression. Neurocognitive outcome did not differ between STABLE plus pharmacotherapy versus pharmacotherapy alone over the 6-month continuation treatment phase. These findings support the safety of RUL-UB ECT in combination with pharmacotherapy in the prolonging of remission in late-life depression. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Electroconvulsive Therapy Pulse Amplitude and Clinical Outcomes.
- Author
-
Abbott, Christopher C., Quinn, Davin, Miller, Jeremy, Ye, Enstin, Iqbal, Sulaiman, Lloyd, Megan, Jones, Thomas R., Upston, Joel, Deng, Zhi De, Erhardt, Erik, and McClintock, Shawn M.
- Abstract
Introduction: Electroconvulsive therapy (ECT) pulse amplitude, which determines the induced electric field magnitude in the brain, is currently set at 800-900 milliamperes (mA) on modern ECT devices without any clinical or scientific rationale. The present study assessed differences in depression and cognitive outcomes for three different pulse amplitudes during an acute ECT series. We hypothesized that the lower amplitudes would maintain the antidepressant efficacy of the standard treatment and reduce the risk of neurocognitive impairment.Methods: This double-blind investigation randomized subjects to three treatment arms: 600, 700, and 800 mA (active comparator). Clinical, cognitive, and imaging assessments were conducted pre-, mid- and post-ECT. Subjects had a diagnosis of major depressive disorder, age range between 50 and 80 years, and met clinical indication for ECT.Results: The 700 and 800 mA arms had improvement in depression outcomes relative to the 600 mA arm. The amplitude groups showed no differences in the primary cognitive outcome variable, the Hopkins Verbal Learning Test-Revised (HVLT-R) retention raw score. However, secondary cognitive outcomes such as the Delis Kaplan Executive Function System Letter and Category Fluency measures demonstrated cognitive impairment in the 800 mA arm.Discussion: The results demonstrated a dissociation of depression (higher amplitudes better) and cognitive (lower amplitudes better) related outcomes. Future work is warranted to elucidate the relationship between amplitude, electric field, neuroplasticity, and clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study.
- Author
-
Lisanby, Sarah H., McClintock, Shawn M., Alexopoulos, George, Bailine, Samuel H., Bernhardt, Elisabeth, Briggs, Mimi C., Cullum, C. Munro, Deng, Zhi-De, Dooley, Mary, Geduldig, Emma T., Greenberg, Robert M., Husain, Mustafa M., Kaliora, Styliani, Knapp, Rebecca G., Latoussakis, Vassilios, Liebman, Lauren S., McCall, William V., Mueller, Martina, Petrides, Georgios, and Prudic, Joan
- Abstract
Objective: There is limited information regarding the tolerability of electroconvulsive therapy (ECT) combined with pharmacotherapy in elderly adults with major depressive disorder (MDD). Addressing this gap, we report acute neurocognitive outcomes from Phase 1 of the Prolonging Remission in Depressed Elderly (PRIDE) study.Methods: Elderly adults (age ≥60) with MDD received an acute course of 6 times seizure threshold right unilateral ultrabrief pulse (RUL-UB) ECT. Venlafaxine was initiated during the first treatment week and continued throughout the study. A comprehensive neurocognitive battery was administered at baseline and 72 hours following the last ECT session. Statistical significance was defined as a two-sided p-value of less than 0.05.Results: A total of 240 elderly adults were enrolled. Neurocognitive performance acutely declined post ECT on measures of psychomotor and verbal processing speed, autobiographical memory consistency, short-term verbal recall and recognition of learned words, phonemic fluency, and complex visual scanning/cognitive flexibility. The magnitude of change from baseline to end for most neurocognitive measures was modest.Conclusion: This is the first study to characterize the neurocognitive effects of combined RUL-UB ECT and venlafaxine in elderly adults with MDD and provides new evidence for the tolerability of RUL-UB ECT in an elderly sample. Of the cognitive domains assessed, only phonemic fluency, complex visual scanning, and cognitive flexibility qualitatively declined from low average to mildly impaired. While some acute changes in neurocognitive performance were statistically significant, the majority of the indices as based on the effect sizes remained relatively stable. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
11. Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial.
- Author
-
Martin, Donel M., McClintock, Shawn M., Aaronson, Scott T., Alonzo, Angelo, Husain, Mustafa M., Lisanby, Sarah H., McDonald, William M., Mohan, Adith, Nikolin, Stevan, O'Reardon, John, Weickert, Cynthia Shannon, and Loo, Colleen K.
- Abstract
Abstract Background Transcranial direct current stimulation (tDCS) has promising antidepressant effects, however, clinical trials have shown variable efficacy. Pre-treatment neurocognitive functioning has previously been identified as an inter-individual predictor of tDCS antidepressant efficacy. Objective In this international multicentre, sham-controlled study, we investigated this relationship while also assessing the influence of clinical and genotype (BDNF Val66Met and COMT Val158Met polymorphisms) factors as predictors of response to active tDCS. Methods The study was a triple-masked, parallel, randomized, controlled design across 6 international academic medical centers. Participants were randomized to active (2.5 mA) or sham (34 μA) tDCS for 30 min each session for 20 sessions. The anode was centered over the left dorsolateral prefrontal cortex at F3 (10/20 EEG system) and the cathode over the lateral right frontal area at F8. Results Better pre-treatment attentional processing speed on the Ruff 2 & 7 Selective Attention Test (Total Speed: β = 0.25, p <.05) and concurrent antidepressant medication use (β = 0.31, p <.05) predicted antidepressant efficacy with active tDCS. Genotype differences in the BDNF Val66Metand COMT Val158Met polymorphisms were not associated with antidepressant effects. Secondary analyses revealed that only participants in the highest performing Ruff 2 & 7 Total Speed group at pre-treatment in both active and sham tDCS conditions showed significantly greater antidepressant response compared to those with lower performance at both the 2 and 4 week treatment time points (p <.05). Conclusions These results suggest that high pre-treatment attentional processing speed may be relevant for identifying participants more likely to show better tDCS antidepressant response to both high (2.5 mA) and very low (34 μA) current intensity stimulation. Clinical trials registration www.clinicaltrials.gov , NCT01562184. Highlights • A predictor analysis from a multicentre trial of tDCS for depression is reported. • Pre-treatment processing speed and medication use predicted response to active tDCS. • Better cognitive performance predicted mood response in both tDCS conditions. • Processing speed may be an important predictor for tDCS antidepressant response. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. International randomized-controlled trial of transcranial Direct Current Stimulation in depression.
- Author
-
Loo, Colleen K., Husain, Mustafa M., McDonald, William M., Aaronson, Scott, O'Reardon, John P., Alonzo, Angelo, Weickert, Cynthia Shannon, Martin, Donel M., McClintock, Shawn M., Mohan, Adith, and Lisanby, Sarah H.
- Abstract
Background Evidence suggests that transcranial Direct Current Stimulation (tDCS) has antidepressant effects in unipolar depression, but there is limited information for patients with bipolar depression. Additionally, prior research suggests that brain derived neurotrophic factor (BDNF) Val66Met genotype may moderate response to tDCS. Objective To examine tDCS efficacy in unipolar and bipolar depression and assess if BDNF genotype is associated with antidepressant response to tDCS. Methods 130 participants diagnosed with a major depressive episode were randomized to receive active (2.5 milliamps (mA), 30 min) or sham (0.034 mA and two 60-second current ramps up to 1 and 0.5 mA) tDCS to the left prefrontal cortex, administered in 20 sessions over 4 weeks, in a double-blinded, international multisite study. Mixed effects repeated measures analyses assessed change in mood and neuropsychological scores in participants with at least one post-baseline rating in the unipolar (N = 84) and bipolar (N = 36) samples. Results Mood improved significantly over the 4-week treatment period in both unipolar ( p = 0.001) and bipolar groups ( p < 0.001). Among participants with unipolar depression, there were more remitters in the sham treatment group ( p = 0.03). There was no difference between active and sham stimulation in the bipolar sample. BDNF genotype was unrelated to antidepressant outcome. Conclusions Overall, this study found no antidepressant difference between active and sham stimulation for unipolar or bipolar depression. However, the possibility that the low current delivered in the sham tDCS condition was biologically active cannot be discounted. Moreover, BDNF genotype did not moderate antidepressant outcome. Clinical Trials Registration www.clinicaltrials.gov , NCT01562184. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Neuromodulation for mood and memory: from the engineering bench to the patient bedside.
- Author
-
Deng, Zhi-De, McClintock, Shawn M, Oey, Nicodemus E, Luber, Bruce, and Lisanby, Sarah H
- Subjects
- *
AFFECTIVE disorders , *ELECTROCONVULSIVE therapy , *GOLD standard , *BRAIN physiology , *CRANIAL nerves - Abstract
Brain stimulation, in the form of electroconvulsive therapy (ECT), has long been a gold standard treatment for depression, but today, the field of neuromodulation is rapidly changing with the advent of newer and more precise tools to alter neuroplasticity and to treat brain-based disorders. Now there are new means to induce focal seizures, as with magnetic seizure therapy (MST), or modifications to ECT. There are also surgical approaches to target brain circuits via implanted stimulators placed in the brain or on cranial nerves. Finally, there are noninvasive subconvulsive approaches for the transcranial application of either electric or magnetic fields. Collectively, these tools have transformed the face of neurotherapeutics and informed our understanding of the brain basis of complex neurobehavioral conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Neural Correlates of Successful Response Inhibition in Unmedicated Patients With Late-Life Depression.
- Author
-
Bobb Jr, David S., Adinoff, Bryon, Laken, Steven J., McClintock, Shawn M., Rubia, Katya, Huang, Hung-wei, Husain, Mustafa M., Mapes, Kimberly S., Tamminga, Carol, Cullum, C. Munro, Gopinath, Kaundinya, Trivedi, Madhukar H., and Kozel, F. Andrew
- Abstract
Objective: Accumulating evidence implicates a strong association between abnormal frontostriatal-limbic brain circuits, executive dysfunction, and late-life depression (LLD). The stop signal task (SST) was designed by Rubia et al. for use with functional magnetic resonance imaging (fMRI) to identify the neural correlates of motor response inhibition, a well-characterized executive function. In this study, we compared brain activation between a group of unmedicated participants with LLD and an unmedicated healthy cohort during SST performance. Methods: Participants 55-85years of age were screened, clinically evaluated, and entered into either the LLD (n = 15) or healthy comparison group (n = 13). Both groups underwent neuro imaging while performing the SST under similar conditions. The brain circuitry of successful motor inhibition was evaluated by contrasting the condition of correctly inhibiting responses with the condition of correctly responding to Go signals. Differential areas of brain activation between the LLD and comparison groups were determined with FMRIB Software Library. Results: Despite comparable SST performance measures, LLD participants demonstrated greater blood oxygen level dependent activation relative to the comparison group in predominantly left-lateralized frontostriatal-limbic circuitry that included the bilateral superior frontal cortices and left-hemispheric orbitofrontal gyri, insular cortex, cingulate cortex, caudate, and putamen. Conversely, the healthy comparison group did not exhibit any areas of greater activation than the LLD group. Conclusion: Unmedicated participants with LLD activate additional areas within frontostriatal-limbic brain circuitry when performing the SST at a level comparable to a healthy cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Transcranial Magnetic Stimulation: A Neuroscientific Probe of Cortical Function in Schizophrenia
- Author
-
McClintock, Shawn M., Freitas, Catarina, Oberman, Lindsay, Lisanby, Sarah H., and Pascual-Leone, Alvaro
- Subjects
- *
TRANSCRANIAL magnetic stimulation , *NEUROSCIENCES , *HIGHER nervous activity , *SCHIZOPHRENIA , *NEUROPSYCHIATRY , *NEUROBIOLOGY , *NEUROPHYSIOLOGY , *BRAIN imaging - Abstract
Transcranial magnetic stimulation (TMS) is a neuropsychiatric tool that can serve as a useful method to better understand the neurobiology of cognitive function, behavior, and emotional processing. The purpose of this article is to examine the utility of TMS as a means to measure neocortical function in neuropsychiatric disorders in general, and schizophrenia in particular, for the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia initiative. When incorporating TMS paradigms in research studies, methodologic considerations include technical aspects of TMS, cohort selection and confounding factors, and subject safety. Available evidence suggests benefits of TMS alone or in combination with neurophysiologic and neuroimaging methods, including positron emission tomography, single photon emission computed tomography, magnetic resonance imaging, functional magnetic resonance imaging, functional near infrared spectroscopy, magnetoencephalography, and electroencephalography, to explore neocortical function. With the multiple TMS techniques including single-pulse, paired-pulse, paired associative stimulation, and repetitive TMS and theta burst stimulation, combined with neurophysiologic and neuroimaging methods, there exists a plethora of TMS experimental paradigms to modulate neocortical physiologic processes. Specifically, TMS can measure cortical excitability, intracortical inhibitory and excitatory mechanisms, and local and network cortical plasticity. Coupled with functional and electrophysiologic modalities, TMS can provide insight into the mechanisms underlying healthy neurodevelopment and aging, as well as neuropsychiatric pathology. Thus, TMS could be a useful tool in the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia armamentarium of biomarker methods. Future investigations are warranted to optimize TMS methodologies for this purpose. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
16. Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment
- Author
-
Buyukdura, Jeylan S., McClintock, Shawn M., and Croarkin, Paul E.
- Subjects
- *
PSYCHOMOTOR disorders , *MENTAL depression , *THERAPEUTICS , *ANTIDEPRESSANTS , *PSYCHIATRIC rating scales , *DEXAMETHASONE , *ELECTROCONVULSIVE therapy , *MONOAMINE oxidase inhibitors , *VASOTOCIN , *ELECTROENCEPHALOGRAPHY - Abstract
Abstract: Psychomotor retardation is a long established component of depression that can have significant clinical and therapeutic implications for treatment. Due to its negative impact on overall function in depressed patients, we review its biological correlates, optimal methods of measurement, and relevance in the context of therapeutic interventions. The aim of the paper is to provide a synthesis of the literature on psychomotor retardation in depression with the goal of enhanced awareness for clinicians and researchers. Increased knowledge and understanding of psychomotor retardation in major depressive disorder may lead to further research and better informed diagnosis in regards to psychomotor retardation. Manifestations of psychomotor retardation include slowed speech, decreased movement, and impaired cognitive function. It is common in patients with melancholic depression and those with psychotic features. Biological correlates may include abnormalities in the basal ganglia and dopaminergic pathways. Neurophysiologic tools such as neuroimaging and transcranial magnetic stimulation may play a role in the study of this symptom in the future. At present, there are three objective scales to evaluate psychomotor retardation severity. Studies examining the impact of psychomotor retardation on clinical outcome have found differential results. However, available evidence suggests that depressed patients with psychomotor retardation may respond well to electroconvulsive therapy (ECT). Current literature regarding antidepressants is inconclusive, though tricyclic antidepressants may be considered for treatment of patients with psychomotor retardation. Future work examining this objective aspect of major depressive disorder (MDD) is essential. This could further elucidate the biological underpinnings of depression and optimize its treatment. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
17. Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: A review.
- Author
-
Moreines, Jared L., McClintock, Shawn M., and Holtzheimer, Paul E.
- Subjects
NEUROPSYCHOLOGY ,TRANSCRANIAL magnetic stimulation ,MENTAL depression ,THERAPEUTICS ,ELECTROCONVULSIVE therapy ,ANTIDEPRESSANTS ,NEURAL stimulation ,VAGUS nerve - Abstract
Electroconvulsive therapy (ECT) and ablative neurosurgical procedures are established interventions for treatment-resistant depression (TRD), but their use may be limited in part by neuropsychological adverse effects. Additional neuromodulation strategies are being developed that aim to match or exceed the efficacy of ECT/ablative surgery with a better neurocognitive side effect profile. In this review, we briefly discuss the neurocognitive effects of ECT and ablative neurosurgical procedures, then synthesize the available neurocognitive information for emerging neuromodulation therapies, including repetitive transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, vagus nerve stimulation, and deep brain stimulation. The available evidence suggests these procedures may be more cognitively benign relative to ECT or ablative neurosurgical procedures, though further research is clearly needed to fully evaluate the neurocognitive effects, both positive and negative, of these novel neuromodulation interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
18. Differential Effects of High-Dose Magnetic Seizure Therapy and Electroconvulsive Shock on Cognitive Function
- Author
-
Spellman, Timothy, McClintock, Shawn M., Terrace, Herbert, Luber, Bruce, Husain, Mustafa M., and Lisanby, Sarah H.
- Subjects
- *
MAGNETOTHERAPY , *COGNITIVE ability , *ELECTROCONVULSIVE therapy , *HIGHER nervous activity - Abstract
Background: Magnetic seizure therapy (MST) is under investigation as an alternative form of convulsive therapy that induces more focal seizures and spares cortical regions involved in memory. With a newly expanded version of the Columbia University Primate Cognitive Profile, we compared the cognitive effects of high-dose MST delivered at 100 Hz (6 × seizure threshold) with electroconvulsive shock (ECS) delivered at 2.5 × seizure threshold. Methods: Daily high-dose MST, ECS, and sham (anesthesia-only) were administered for 4 weeks each in a within-subject crossover design. Rhesus macaques (n = 3) were trained on five cognitive tasks assessing automatic memory, anterograde learning and memory, combined anterograde and retrograde simultaneous chaining, and spatial and serial working memory. Acutely after each intervention, monkeys were tested on the cognitive battery twice daily, separated by a 3-hour retention interval. Results: Subjects were slower to complete criterion tasks (p values < .0001) after ECS, compared with sham and high-dose MST. Moreover, time to task-completion after high-dose MST did not differ from sham. Of six measures of accuracy, treatment effects were found in four; in all of these, ECS but not MST fared worse than sham. On all accuracy and time to completion measurements, subjects performed as well after high-dose MST as subjects from a previous study on moderate-dose MST. Conclusions: These findings provide evidence that high-dose MST results in benign acute cognitive side-effect profile relative to ECS and are in line with our previous studies. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
19. The NIH Toolbox: Assessing the Function of Cognitive, Sensory, Motor, and Emotion Domains in Patients Diagnosed with Parkinson's Disease.
- Author
-
Williams, Claire A., Husain, Mustafa M., McClintock, Shawn M., and Arslanagic, Enisa
- Published
- 2013
- Full Text
- View/download PDF
20. 17. Predictors of Remission After Repetitive Transcranial Magnetic Stimulation for the Treatment of Late-Life Depression.
- Author
-
Göke, Katharina, Trevizol, Alisson P., Ma, Clement, Mah, Linda, Rajji, Tarek K., Daskalakis, Zafiris J., Downar, Jonathan, McClintock, Shawn M., Nestor, Sean M., Noda, Yoshihiro, and Blumberger, Daniel M.
- Subjects
- *
TRANSCRANIAL magnetic stimulation , *MENTAL depression - Published
- 2024
- Full Text
- View/download PDF
21. The Effect of Cognitive Functioning on Treatment Attendance and Adherence in Comorbid Bipolar Disorder and Cocaine Dependence.
- Author
-
Fagan, Colleen S., Carmody, Thomas J., McClintock, Shawn M., Suris, Alina, Nakamura, Alyson, Jeon-Slaughter, Haekyung, Lo, Alexander, and Brown, E. Sherwood
- Subjects
- *
COGNITIVE ability , *BIPOLAR disorder , *COCAINE , *COGNITION disorders , *CLINICAL trials , *NEUROPSYCHOLOGY - Abstract
Although bipolar disorder and substance dependence are both associated with treatment non-adherence and cognitive impairment, no studies have investigated relationships between treatment adherence and cognitive functioning in this population. As part of a clinical trial, baseline performance on two neuropsychological tests in 120 outpatients with bipolar disorder and cocaine dependence was used to examine whether cognitive functioning was associated with appointment attendance, medication adherence, and return of medication bottles. This study found that higher baseline cognitive functioning measured by the Stroop Color–Word condition predicted better treatment adherence. However, this study also reports measurement sensitivity of cognition as it relates to treatment adherence when applied to this dual diagnosis population. Poorer performance in simple visual attention tasks as assessed by the Stroop Word condition was inversely associated with some measures of adherence. Future studies are warranted that include a comprehensive neuropsychological battery and advanced medication adherence measures to confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. Cognitive effects of transcranial direct current stimulation treatment in patients with major depressive disorder: An individual patient data meta-analysis of randomised, sham-controlled trials.
- Author
-
Martin, Donel M., Moffa, Adriano, Nikolin, Stevan, Bennabi, Djamila, Brunoni, André R., Flannery, William, Haffen, Emmanuel, Mcclintock, Shawn M., Moreno, Marina L., Padberg, Frank, Palm, Ulrich, and Loo, Colleen K.
- Subjects
- *
TRANSCRANIAL direct current stimulation , *MENTAL depression , *THERAPEUTICS , *BIPOLAR disorder , *META-analysis , *COGNITION disorders , *PATIENTS - Abstract
Transcranial direct current stimulation (tDCS) has emerged as a promising new treatment for major depression. While recent randomised, sham-controlled studies found tDCS to have antidepressant effects, it remains to be determined whether a tDCS treatment course may also enhance cognitive function independent of mood effects in depressed patients. This systematic review and individual patient data (IPD) meta-analysis examined cognitive outcomes from randomised, sham-controlled trials of tDCS treatment for major depression. Seven randomised, sham-controlled trials (n = 478 participants, 260 in active and 218 in sham) of tDCS for major depression were included. Results showed no cognitive enhancement after active tDCS compared to sham for the 12 cognitive outcomes investigated. Active relative to sham tDCS treatment was associated with reduced performance gains on a measure of processing speed (β = −0.33, 95% CI −0.58; −0.08, p = 0.011). Active tDCS treatment for depression did not show cognitive benefits independent of mood effects. Rather, tDCS treatment relative to sham stimulation for major depression may instead be associated with a reduced practice effect for processing speed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial.
- Author
-
McCall, W. Vaughn, Lisanby, Sarah H., Rosenquist, Peter B., Dooley, Mary, Husain, Mustafa M., Knapp, Rebecca G., Petrides, Georgios, Rudorfer, Matthew V., Young, Robert C., McClintock, Shawn M., Mueller, Martina, Prudic, Joan, Greenberg, Robert M., Weiner, Richard D., Bailine, Samuel H., Youssef, Nagy A., McCloud, Laryssa, and Kellner, Charles H.
- Subjects
- *
ELECTROCONVULSIVE therapy , *QUALITY of life , *MENTAL depression , *CLINICAL trials , *OLDER patients , *MENTAL health - Abstract
We examined whether electroconvulsive therapy (ECT) plus medications (“STABLE + PHARM” group) had superior HRQOL compared with medications alone (“PHARM” group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the “STABLE + PHARM” group versus the “PHARM” group. The overall study design was called “Prolonging Remission in Depressed Elderly” (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of “STABLE + PHARM” versus “PHARM”. Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The “PHARM” group received venlafaxine and lithium. The “STABLE + PHARM” received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7%) with a mean age of 70.5 ± 7.2 years. “STABLE + PHARM” patients received 4.5 ± 2.5 ECT sessions during Phase 2. “STABLE + PHARM” group had 7 point advantage (3.5–10.4, 95% CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2–12.2, 95% CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. Clinical Trials.gov NCT01028508 [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Effects of a right unilateral ultrabrief pulse electroconvulsive therapy course on health related quality of life in elderly depressed patients.
- Author
-
Vaughn McCall, W., Lisanby, Sarah H., Rosenquist, Peter B., Dooley, Mary, Husain, Mustafa M., Knapp, Rebecca G., Petrides, Georgios, Rudorfer, Matthew V., Young, Robert C., McClintock, Shawn M., Mueller, Martina, Prudic, Joan, Greenberg, Robert M., Weiner, Richard D., Bailine, Samuel H., Riley, Mary Anne, McCloud, Laryssa, Kellner, Charles H., CORE/PRIDE Work Group, and McCall, W Vaughn
- Subjects
- *
MENTAL depression , *ELECTROCONVULSIVE therapy , *COGNITIVE ability , *QUALITY of life , *AFFECTIVE disorders , *THERAPEUTICS , *COGNITION , *HEALTH status indicators , *NEUROPSYCHOLOGICAL tests , *PSYCHOLOGICAL tests , *QUESTIONNAIRES , *RESEARCH funding , *TREATMENT effectiveness , *DISEASE remission - Abstract
Introduction: Patients with Major Depressive Disorder (MDD) referred for electroconvulsive therapy (ECT) have poorer Health Related Quality of Life (HRQOL), compared with other patients with MDD, but ECT is associated with significant and durable improvement in HRQOL. However, no prior research has focused exclusively on elderly patients with MDD receiving ECT.Methods: HRQOL data from 240 depressed patients over the age of 60 was measured with the Medical Outcomes Study Short Form 36 (SF-36). The SF-36 was measured before and after a course of acute ECT. Predictors of change in HRQOL scores were identified by generalized linear modeling.Results: At baseline, participants showed very poor HRQOL. After treatment with ECT, the full sample showed marked and significant improvement across all SF-36 measures, with the largest gains seen in dimensions of mental health. Across all participants, the Physical Component Summary (PCS) score improved by 2.1 standardized points (95% CI, 0.61,3.56), while the Mental Component Summary (MCS) score improved by 12.5 points (95% CI, 7.2,10.8) Compared with non-remitters, remitters showed a trend toward greater improvement in the PCS summary score of 2.7 points (95%CI, -0.45, 5.9), while the improvement in the MCS summary score was significantly greater (8.5 points, 95% CI, 4.6,12.3) in the remitters than non-remitters. Post-ECT SF-36 measurements were consistently and positively related to baseline scores and remitter/non-remitter status or change in depression severity from baseline. Objective measures of cognitive function had no significant relationships to changes in SF-36 scores.Limitations: This study's limitations include that it was an open label study with no comparison group, and generalizability is limited to elderly patients.Discussion: ECT providers and elderly patients with MDD treated with ECT can be confident that ECT will result in improved HRQOL in the short-term. Attaining remission is a key factor in the improvement of HRQOL. Acute changes in select cognitive functions were outweighed by improvement in depressive symptoms in determining the short term HRQOL of the participants treated with ECT. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
25. Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression.
- Author
-
Alonzo, Angelo, Aaronson, Scott, Bikson, Marom, Husain, Mustafa, Lisanby, Sarah, Martin, Donel, McClintock, Shawn M., McDonald, William M., O'Reardon, John, Esmailpoor, Zeinab, and Loo, Colleen
- Subjects
- *
BIPOLAR disorder , *THERAPEUTICS , *TRANSCRANIAL direct current stimulation , *RANDOMIZED controlled trials , *ANTIDEPRESSANTS , *HEALTH outcome assessment - Abstract
Transcranial Direct Current Stimulation (tDCS) is a new, non-invasive neuromodulation approach for treating depression that has shown promising efficacy. The aim of this trial was to conduct the first international, multicentre randomised controlled trial of tDCS as a treatment for unipolar and bipolar depression. The study recruited 120 participants across 6 sites in the USA and Australia. Participants received active or sham tDCS (2.5 mA, 20 sessions of 30 min duration over 4 weeks), followed by a 4-week open label active treatment phase and a 4-week taper phase. Mood and neuropsychological outcomes were assessed with the primary antidepressant outcome measure being the Montgomery-Asberg Depression Rating Scale (MADRS). A neuropsychological battery was administered to assess safety and examine cognitive effects. The study also investigated the possible influence of genetic polymorphisms on outcomes. The trial was triple-blinded. Participants, tDCS treaters and study raters were blinded to each participant's tDCS group allocation in the sham-controlled phase. Specific aspects of tDCS administration, device operation and group allocation were designed to optimise the integrity of blinding. Outcome measures will be tested using a mixed effects repeated measures analysis with the primary factors being Time as a repeated measure, tDCS condition (sham or active) and Diagnosis (unipolar or bipolar). A restricted number of random and fixed factors will be included as required to account for extraneous differences. As a promising treatment, tDCS has excellent potential for translation into widespread clinical use, being cost effective, portable, easy to operate and well tolerated. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. 7, 8-Dihydroxyflavone induces synapse expression of AMPA GluA1 and ameliorates cognitive and spine abnormalities in a mouse model of fragile X syndrome.
- Author
-
Tian, Mi, Zeng, Yan, Hu, Yilan, Yuan, Xiuxue, Liu, Shumin, Li, Jie, Lu, Pan, Sun, Yao, Gao, Lei, Fu, Daan, Li, Yi, Wang, Shasha, and McClintock, Shawn M.
- Subjects
- *
FRAGILE X syndrome , *FLAVONES , *SYNAPSES , *GENE expression , *AMPA receptors , *COGNITION disorders , *SPINE abnormalities , *LABORATORY mice - Abstract
Fragile X syndrome (FXS) is characterized by immature dendritic spine architectures and cognitive impairment. 7, 8-Dihydroxyflavone (7, 8-DHF) has recently been identified as a high affinity tropomyosin receptor kinase B (TrkB) agonist. The purpose of this paper was to examine the utility of 7, 8-DHF as an effective pharmacotherapeutic agent that targets dendritic pathology and cognitive impairments in FXS mutant. We synthesized pharmacologic, behavioral, and biochemical approaches to examine the effects of 7, 8-DHF on spatial and fear memory functions, and morphological spine abnormalities in fragile X mental retardation 1 ( Fmr1 ) gene knock-out mice. The study found that 4 weeks of treatment with 7, 8-DHF improved spatial and fear memory, and ameliorated morphological spine abnormalities including the number and elongation of spines in the hippocampus and amygdala. Further mechanism analysis revealed that 7, 8-DHF enhanced the expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) GluA1 receptor, but reduced the normal levels of GluA2 at the synapses in Fmr1 . Potentially related to drug-induced changes in AMPA receptor subunits, 7, 8-DHF at the synapses led to phosphorylation of specific serine sites on subunits Ser818 and Ser813 of GluA1, and Ser880 of GluA2, as well as phosphorylation of TrkB, calcium/calmodulin-dependent protein kinase II, and protein kinase C. However, 7, 8-DHF neither affected behavioral performance nor increased TrkB phosphorylation in WT mice, which suggested that it had FXS-specific correcting effect. Altogether, these results demonstrated that 7, 8-DHF improved learning and memory, and reduced abnormalities in spine morphology, thus providing a potential pharmacotherapeutic strategy for FXS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. Pain in depression: STAR*D study findings
- Author
-
Husain, Mustafa M., Rush, A. John, Trivedi, Madhukar H., McClintock, Shawn M., Wisniewski, Stephen R., Davis, Lori, Luther, James F., Zisook, Sid, and Fava, Maurizio
- Subjects
- *
DEPRESSED persons , *MENTAL depression , *AUTONOMIC nervous system , *SYMPATHETIC nervous system - Abstract
Abstract: Background: Pain complaints commonly accompany major depressive disorder (MDD). However, whether patients with MDD and pain complaints differ from those without pain complaints is not well studied. Objective: The objective of this study was to compare depressed outpatients with and those without current pain complaints in terms of sociodemographic, clinical, and presenting symptom features. Methods: The baseline clinical and sociodemographic data of a large representative outpatient sample with nonpsychotic MDD (n=3745) enrolled in the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study were collected. Baseline information on pain complaints was based on Item No. 25 (somatic pain) of the 30-item Inventory of Depressive Symptomatology–Clinician Rating (IDS-C30). Results: After adjusting for sex, depression severity (IDS-C30 less Item No. 25), and general medical comorbidities (as measured by the Cumulative Illness Rating Scale total score), we found clinically meaningful differences between patients with and those without pain complaints. Younger, African American, Hispanic, and less educated patients were more likely to report pain complaints. In addition, those with pain complaints were more likely to report anxious features with irritable mood, sympathetic nervous system arousal, and gastrointestinal problems as well as poorer quality of life. Neither a more chronic course of illness nor suicidal ideation was associated with pain. Conclusions: Pain complaints are common among outpatients with MDD and are associated with certain symptom features and poorer quality of life. However, the findings of this study suggest that depression accompanied by pain complaints does not increase the clinical psychiatric burden or chronicity of depression. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.